Mendham, New Jersey
United States
451
2021-11-11
The entities that hold a legal rights for patent applications filed by inventor Goldenberg David M.:
David M. Goldenberg from Mendham, US has applied for patents for these inventions. The list has both pending applications and granted patents:
IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
#2 | 2020-10-08Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#3 | 2020-09-03Immunoconjugates with an intracellularly-cleavable linkage
#4 | 2020-08-06Antibody-drug conjugates and uses thereof
#5 | 2019-08-15Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#6 | 2019-07-11Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
#7 | 2019-06-13Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
#8 | 2019-06-06Immunoconjugates with an intracellularly-cleavable linkage
#9 | 2019-05-16COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE
#10 | 2019-03-21RS7 Antibodies
#11 | 2019-03-07Antibody-drug conjugates and uses thereof
#12 | 2019-01-31Antibody-SN-38 immunoconjugates with a CL2A linker
#13 | 2019-01-17Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#14 | 2018-11-08Immunoconjugates with an intracellularly-cleavable linkage
#15 | 2018-10-18NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
#16 | 2018-10-04Subcutaneous administration of antibody-drug conjugates for cancer therapy
#17 | 2018-09-27Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
#18 | 2018-09-06RS7 antibodies
#19 | 2018-07-05Murine, chimeric, humanized or human anti-TNF-alpha antibodies
#20 | 2018-07-05Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
#21 | 2018-06-21Chimeric and humanized anti-histone antibodies
#22 | 2018-06-14Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
#23 | 2018-06-14Antibody-SN-38 immunoconjugates with a CL2A linker
#24 | 2018-05-31Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
#25 | 2018-05-17RS7 antibodies
#26 | 2018-05-03Disease therapy by inducing immune response to Trop-2 expressing cells
#27 | 2018-04-26Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#28 | 2018-03-29Antibody-SN-38 immunoconjugates with a CL2A linker
#29 | 2018-03-22Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors
#30 | 2018-02-22Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
#31 | 2018-01-25Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies
#32 | 2017-12-21Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#33 | 2017-11-23FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES
#34 | 2017-11-16CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS
#35 | 2017-11-09Isolated nucleic acid encoding an anti-IGF-1R antibody
#36 | 2017-11-02Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
#37 | 2017-10-05Murine, chimeric, humanized or human anti-IL-6 antibodies
#38 | 2017-10-05Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules
#39 | 2017-10-05ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#40 | 2017-10-05Combination therapy for inducing immune response to disease
#41 | 2017-09-28Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
#42 | 2017-09-28Humanized anti-CD22 antibody
#43 | 2017-09-28COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER
#44 | 2017-09-28RS7 antibodies
#45 | 2017-09-21Immunoconjugates with an intracellularly-cleavable linkage
#46 | 2017-09-21PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#47 | 2017-09-21Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
#48 | 2017-09-14Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
#49 | 2017-08-31T-cell redirecting bispecific antibodies for treatment of disease
#50 | 2017-08-31T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
#51 | 2017-08-24Immunoconjugates with an intracellularly-cleavable linkage
#52 | 2017-08-10Disease therapy by inducing immune response to Trop-2 expressing cells
#53 | 2017-08-10Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#54 | 2017-08-10COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
#55 | 2017-08-03Methods for treating thrombosis using chimeric and humanized anti-histone antibodies
#56 | 2017-08-03Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
#57 | 2017-07-27Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
#58 | 2017-06-22Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments
#59 | 2017-06-15Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
#60 | 2017-06-15Antibody-SN-38 immunoconjugates with a CL2A linker
#61 | 2017-06-01Anti-CD19 Antibodies
#62 | 2017-06-01Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases
#63 | 2017-05-18Anti-Pancreatic Cancer Antibodies
#64 | 2017-05-04Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses
#65 | 2017-03-30Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#66 | 2017-03-30Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#67 | 2017-03-09Humanized anti-HLA-DR antibodies
#68 | 2017-03-02Tetrameric cytokines with improved biological activity
#69 | 2017-02-09Detection of Early-Stage Pancreatic Adenocarcinoma
#70 | 2017-02-02Immunoconjugates with an intracellularly-cleavable linkage
#71 | 2017-01-26T-cell redirecting bispecific antibodies for treatment of disease
#72 | 2017-01-26Combination therapy for inducing immune response to disease
#73 | 2017-01-19Antibody-drug conjugates and uses thereof
#74 | 2017-01-19Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#75 | 2017-01-12METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
#76 | 2017-01-05Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#77 | 2016-12-29Humanized anti-CD22 antibody
#78 | 2016-12-29Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
#79 | 2016-12-22Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#80 | 2016-12-15PEGylation by the dock and lock (DNL) technique
#81 | 2016-12-15Dock-and-Lock (DNL) Vaccines for Cancer Therapy
#82 | 2016-12-15DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS
#83 | 2016-12-08SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
#84 | 2016-12-01ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)
#85 | 2016-12-01T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
#86 | 2016-11-24Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
#87 | 2016-11-17Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#88 | 2016-11-03Anti-CD19 antibodies
#89 | 2016-10-27Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
#90 | 2016-10-27BISPECIFIC ANTIBODIES THAT NEUTRALIZE BOTH TNF-ALPHA AND IL-6: NOVEL THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE
#91 | 2016-10-20COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#92 | 2016-10-20Antibody-SN-38 immunoconjugates with a CL2A linker
#93 | 2016-10-13Y-90-LABELED ANTI-CD22 ANTIBODY (EPRATUZUMAB TETRAXETAN) IN REFRACTORY/RELAPSED ADULT CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#94 | 2016-10-13Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
#95 | 2016-10-06TUMOR THERAPY BY BISPECIFIC ANTIBODY PRETARGETING
#96 | 2016-09-29SUBCUTANEOUS ADMINISTRATION OF ANTI-CD74 ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTOIMMUNE DISEASE
#97 | 2016-09-15Disease therapy by inducing immune response to Trop-2 expressing cells
#98 | 2016-09-08Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#99 | 2016-09-08Antibody-SN-38 immunoconjugates with a CL2A linker
#100 | 2016-09-01THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR INDUCING TROGOCYTOSIS
52192 ⎘